CEDIE   05498
CENTRO DE INVESTIGACIONES ENDOCRINOLOGICAS "DR. CESAR BERGADA"
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Sertoli cell function during chemotherapy in pediatric patients with acute lymphoblastic leukemia (ALL)
Autor/es:
GRINSPON R.P ; GUTIÉRREZ M.E; BALLERINI M.G; PRADA S; ROPELATO M. G; REY R.A; AROZARENA DE GAMBOA M,; BEDECARRAS P; AVERSA L
Lugar:
Buenos Aires
Reunión:
Congreso; XXI Reunión Sociedad Latinoamericana Endocrinología Pediátrica; 2016
Institución organizadora:
Sociedad Latinoamericana Endocrinología Pediátrica
Resumen:
Background: Most reports on gonadotoxicity associated withchemotherapy of acute lymphoblastic leukemia (ALL) comes fromstudies in adults, and they are mainly focused on the sensitivity oftesticular germ cells. Little attention has been placed on Sertoli cellsin prepubertal patients, even though Sertoli cell function is essentialfor adult spermatogenesis.Objective: To evaluate Sertoli cell function in prepubertal boyswho receive chemotherapy for acute lymphoblastic leukemia.Materials and Methods: A prospective study including prepubertalmale patients with ALL. Main outcome measure was serumAMH level after each phase of chemotherapy and 1 year after treatmentcompletion. Secondarily, FSH levels were measured. Resultsare expressed as medians (range).Results: 26 boys with ALL were included: 24 had LLAB and 2LLAT (4 standard, 14 medium and 8 high-risk ALL), age at diagnosiswas 4.2 yr (0.4?14.3).Serum AMH was: at diagnosis, 605 pmol/L (152?1333); at theend of induction (n = 19), 833 (170?1697) = 143% of pre-treatmentlevel (92?274); after intensification (n: 23), 742 (240?1660) = 138%(58?251); after Phase 1 (n = 14), 644 (265?1095) = 112% (53?150);prior to start of maintenance (n = 16), 674 (351?1300) = 109%(67?199); at 6 months of maintenance (n = 11), 695 (312?1386) =104% (63?215); at the end of treatment (n = 7), 817 (523?1563) =131% (87?291); and 3 months after the end of treatment (n = 5),738 (396?1336) = 107% (75?123) of pre-treatment AMH level. SerumAMH decreased below 70% of pre-treatment level during chemotherapyin 6 of 8 patients with high risk ALL, in 1 of 14 withmedium risk and in none with standard risk. Only 6 patients (23%)had a transient mild FSH elevation.Conclusion: These preliminary results showed that Sertoli cellfunction is not affected by chemotherapy in prepubertal boys withstandard or medium risk ALL, but is at least transiently affected inthose with high risk LLA.